Literature DB >> 18077618

Implications of Streptococcus pneumoniae penicillin resistance and serotype distribution in Kuwait for disease treatment and prevention.

Eiman M Mokaddas1, Vincent O Rotimi, M John Albert.   

Abstract

Streptococcus pneumoniae causes serious infections. Treatment is difficult because of the emergence of penicillin resistance in S. pneumoniae. Pneumococcal vaccines offer the promise of control and prevention of pneumococcal infections. Serotype prevalence and penicillin susceptibility data for a country will predict the usefulness of the vaccines in that country. In Kuwait, the 23-valent polysaccharide and the 7-valent conjugate vaccines are being used without knowledge of the prevalent serotypes in the country. To obtain the necessary background information, data on penicillin susceptibility and serogroups were obtained from 397 consecutive clinical isolates collected during 2004 and 2005. Two hundred fifty-three isolates (64%) were penicillin resistant, and resistance was significantly higher in patients < or =15 years old and among the upper respiratory tract and eye isolates. The most common serotypes were 23F, 19F, 6A, 6B, 14, and 19A. Among the penicillin-resistant strains, the most common serotypes were 23F, 19F, 6B, 14, and 9A. Among the invasive strains, the most common serotypes were 14, 23F, 19A, and 9V. The polysaccharide vaccine gave 82% coverage against invasive infections in all age groups >2 years. The coverage of the 7-valent conjugate vaccine against invasive serotypes in children < or =2 years old was 55%. This moderate coverage by the conjugate vaccine against invasive infections in children necessitates a revised strategy on the use of the present conjugate vaccine and shows the need for formulation of an improved vaccine for superior coverage for Kuwait and possibly other countries of the Arabian Gulf.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077618      PMCID: PMC2238047          DOI: 10.1128/CVI.00277-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  29 in total

1.  Antimicrobial resistance with Streptococcus pneumoniae in the United States.

Authors:  G V Doern
Journal:  Semin Respir Crit Care Med       Date:  2000       Impact factor: 3.119

2.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

3.  The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Authors:  W P Hausdorff; J Bryant; C Kloek; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

4.  Typing of pneumococci by using 12 pooled antisera.

Authors:  U B Sørensen
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

5.  Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-10-06

6.  Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait.

Authors:  E M Mokaddas; S Wilson; S C Sanyal
Journal:  J Chemother       Date:  2001-04       Impact factor: 1.714

7.  Comparison of antibiotic resistance and serotype composition of carriage and invasive pneumococci among Bangladeshi children: implications for treatment policy and vaccine formulation.

Authors:  Samir K Saha; Abdullah H Baqui; Gary L Darmstadt; M Ruhulamin; Mohammed Hanif; Shams El Arifeen; Mathuram Santosham; Kazunori Oishi; Tsuyoshi Nagatake; Robert E Black
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

8.  Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group.

Authors:  S L Deeks; R Palacio; R Ruvinsky; D A Kertesz; M Hortal; A Rossi; J S Spika; J L Di Fabio
Journal:  Pediatrics       Date:  1999-02       Impact factor: 7.124

9.  Penicillin resistance in serogroups/serotypes of Streptococcus pneumoniae causing invasive infections in Central Saudi Arabia.

Authors:  Kingsley Twum-Danso; Abdulrahman M Al-Mazrou; Abdel-Mageed M Kambal; Fahad A Al-Zamil
Journal:  Saudi Med J       Date:  2003-11       Impact factor: 1.484

10.  Consumer attitudes and use of antibiotics.

Authors:  Jodi Vanden Eng; Ruthanne Marcus; James L Hadler; Beth Imhoff; Duc J Vugia; Paul R Cieslak; Elizabeth Zell; Valerie Deneen; Katherine Gibbs McCombs; Shelley M Zansky; Marguerite A Hawkins; Richard E Besser
Journal:  Emerg Infect Dis       Date:  2003-09       Impact factor: 6.883

View more
  9 in total

1.  Comparison of transformation frequencies among selected Streptococcus pneumoniae serotypes.

Authors:  Moses L Joloba; Benson R Kidenya; David P Kateete; Fred A Katabazi; Julian K Muwanguzi; Benon B Asiimwe; Simon P Alarakol; Jessica L Nakavuma; Saralee Bajaksouzian; Anne Windau; Michael R Jacobs
Journal:  Int J Antimicrob Agents       Date:  2010-05-15       Impact factor: 5.283

2.  Serotype Prevalence and Penicillin-susceptibility of Streptococcus pneumoniae in Oman.

Authors:  Mubarak M Al-Yaqoubi; Kamal M Elhag
Journal:  Oman Med J       Date:  2011-01

3.  Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide.

Authors:  Mehmet Ceyhan; Nezahat Gurler; Akgun Yaman; Candan Ozturk; Lutfiye Oksuz; Sengul Ozkan; Melike Keser; Nuran Salman; Emre Alhan; Duygu Esel; Meral Gultekin; Yildiz Camcioglu; Mustafa Gul; Yelda Sorguc; Sohret Aydemir; Murat Gunaydin; Yusuf Yakupogullari; Ahmet Kizirgil
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

4.  The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019.

Authors:  Eiman Mokaddas; Shabeera Syed; M John Albert
Journal:  Hum Vaccin Immunother       Date:  2021-08-26       Impact factor: 4.526

5.  Retrospective review of invasive pediatric pneumococcal diseases in a military hospital in the southern region of Saudi Arabia.

Authors:  Mohammed Saeed Al Ayed; Ali Abdullah Hawan
Journal:  Ann Saudi Med       Date:  2011 Sep-Oct       Impact factor: 1.526

6.  Serotype distribution and drug resistance in Streptococcus pneumoniae, Palestinian Territories.

Authors:  Randa Kattan; Amal Abu Rayyan; Inas Zheiman; Suzan Idkeidek; Sabri Baraghithi; Nabeel Rishmawi; Sultan Turkuman; Afaf Abu-Diab; Riyad Ghneim; Madeleine Zoughbi; Rula Dauodi; Raed Ghneim; Abed-El-Razeq Issa; Issa Siryani; Randa Al Qas; Rawan Liddawi; Hatem Khamash; Moein Kanaan; Hiyam Marzouqa; Musa Y Hindiyeh
Journal:  Emerg Infect Dis       Date:  2011-01       Impact factor: 6.883

7.  Antimicrobial Susceptibilities and Distribution of Resistance Genes for β-Lactams in Streptococcus pneumoniae Isolated in Hamadan.

Authors:  Mohammad Najafi Mosleh; Marzieh Gharibi; Mohammad Yousef Alikhani; Massoud Saidijam; Giti Kalantarian
Journal:  Jundishapur J Microbiol       Date:  2014-10-01       Impact factor: 0.747

8.  Ketoacidosis at first presentation of type 1 diabetes mellitus among children: a study from Kuwait.

Authors:  Azza Aly Shaltout; Arshad Mohamed Channanath; Thangavel Alphonse Thanaraj; Dina Omar; Majedah Abdulrasoul; Nabila Zanaty; Maria Almahdi; Hessa Alkandari; Dalia AlAbdulrazzaq; Linda d'Mello; Fawziya Mandani; Ayed Alanezi; Eman AlBasiry; M Alkhawari
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379

Review 9.  Epidemiology of community-acquired pneumonia and implications for vaccination of children living in developing and newly industrialized countries: A systematic literature review.

Authors:  Rodrigo DeAntonio; Juan-Pablo Yarzabal; James Philip Cruz; Johannes E Schmidt; Jos Kleijnen
Journal:  Hum Vaccin Immunother       Date:  2016-06-07       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.